BioSpace News Archive

Veterinary vaccines are the vaccines that are mainly used to increase immunity of animals.

Demand for bioengineered protein drugs is on an upward rise as awareness regarding their success rate, safety, specificity, and bio-reactivity catches on with people.

Advances in medical science has led to evolution in therapeutics and diagnostic process of diseases.

Today, Drug Innovation Ventures at Emory (DRIVE), a nonprofit biotechnology company owned by Emory University, launched a GoFundMe charity campaign to help accelerate testing for its antiviral compound that could potentially be used to treat the new coronavirus associated with the outbreak in China and spreading around the globe.

Launch Ocular Partners, Inc. - Leading Ophthalmology Practice Management Platform in the Midwest

Triple-S Management Corporation (NYSE: GTS), a leading managed care company in Puerto Rico, today announced its fourth quarter 2019 results.

NeuroVasc Technologies, Inc. announced that it has entered into a strategic partnership with the Wego Group that includes $34 million in funding to support the company’s product portfolio development and global clinical trial program.

Harbour BioMed (HBM) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application for a Phase 2 clinical trial of HBM9167, its humanized IgG1 monoclonal antibody targeting programmed death-ligand 1 (PD-L1), for the treatment of nasopharyngeal cancer (NPC

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biopharmaceutical company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced new pre-clinical findings in connection with its on-going collaboration with Univo Pharmaceuticals (TASE:UNVO), demonstrating CBD’s robust anti-neoplastic effect in pre-clinical studies against liver cancer.

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its fourth quarter and full year 2019 financial results will be reported on Wednesday, March 11, 2020 after the close of the financial markets.